Table 1.
Basic characteristics of included studies.
| Study | Country | Patients (n) | Sex (M/F) | TNM stage (n) | cut-off value with HR (P value) | calculation method for cut-off value | NOS | ||
|---|---|---|---|---|---|---|---|---|---|
| NLR | MLR/LMR | PLR | |||||||
| Wu (9) | China | 85 | NR | I/II/III/IV (21/13/47/6) | 2.3 1.77 (0.016) | NR | NR | median value of effect size | 9 |
| Gao (10) | China | 90 | 47/43 | I/II/III/IV (54/11/23/2) | 5 3.09 (0.027) | NR | NR | refer to others | 8 |
| Zhang (11) | China | 145 | 68/77 | I/II/III/IV (7/12/75/51) | 1.94 | NR | 113.3 | ROC curve | 8 |
| 2.73 (0.001) | 1.74 (0.001) | ||||||||
| Beal (12) | America | 187 | NR | NR | 5 | NR | NR | refer to others | 8 |
| 3.52 (0.02) | |||||||||
| Zhang (13) | China | 316 | 215/101 | I–II/III–IV (28/288) | 2.61 | NR | NR | ROC curve | 8 |
| 1.65 (0.008) | |||||||||
| Cui (14) | China | 159 | NR | I/II/III/IV (13/27/50/69) | 4.39 | 0.30/NR | 181 | ROC curve | 8 |
| 1.57 (0.01) | 1.61 (0.006) | 1.24 (0.23) | |||||||
| Tao (15) | China | 84 | 28/56 | III/IV (35/49) | 3.2 | 0.25/NR | 117.7 | ROC curve | 9 |
| 2.348 (0.002) | 2.42 (0.001) | 1.859 (0.024) | |||||||
| Du (16) | China | 220 | 122/98 | NR | 5.1 | NR/2.92 | 178 | X‐tile software | 7 |
| 1.38 (0.62) | 0.69 (0.03) | 0.75 (0.44) | |||||||
| Choi (17) | South Korea | 178 | 95/83 | III/IV (39/139) | 2 | 0.24/NR | 108 | refer to others | 9 |
| 2.06 (0.001) | 2.53 (0.001) | 1.69 (0.019) | |||||||
| Deng (18) | China | 169 | 55/114 | I/II/III/IV (16/37/76/40) | 2.61 | NR/2.66 | 145.3 | ROC curve | 8 |
| 3.30 (0.008) | 1.55 (0.027) | 1.221 (0.376) | |||||||
| Liu (19) | China | 90 | NR | I–II/III–IV (20/70) | 4.33 | NR | NR | mean value of effect size | 7 |
| 3.84 (0.01) | |||||||||
| Navarro (20) | South Korea | 197 | 83/114 | II/III/IV (148/41/8) | 2.4 | NR/4 | 148 | ROC curve | 8 |
| 1.80 (0.44) | 1.25 (0.739) | 0.53 (0.432) | |||||||
| You (21) | South Korea | 173 | 87/86 | III/IV/IV (1/8/164) | 3 | NR | 190 | refer to others | 8 |
| 1.65 (0.017) | 1.19 (0.405) | ||||||||
| Mady (22) | America | 231 | 72/159 | NR | 5 | NR | NR | refer to others | 9 |
| 1.70 (0.003) | |||||||||
TNM, tumor/node/metastasis stages; HR, Hazard Ratio; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; PLR, platelet-to-lymphocyte ratio; NR, not reported; ROC, receiver operating characteristic; NOS, Newcastle–Ottawa Scale.